• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$69.71 -$0.29 (-0.41%)

REAL-TIME: Last trade at

Haemonetics Corp

NYSE:HAE

Jump to this page for:

Related Resources

Haemonetics to Present at the Jefferies 2012 Global Healthcare Conference

5/22/2012 by PR Newswire

Haemonetics to host analyst and investor day

5/9/2012 by Theflyonthewall.com

Haemonetics upgraded to Overweight from Equal Weight at Stephens

5/1/2012 by Theflyonthewall.com

Haemonetics Corp. (HAE) Rose Past Resistance At The Highs

5/1/2012 by RTTNews

4 Stocks Hit 52-Week Highs: Kraft, Comcast

4/30/2012 by TheStreet.com

Haemonetics in two deals worth $578 million

4/30/2012 by Boston Business Journal - Boston MA

Haemonetics Rev Up, Eyes Acquisition

4/30/2012 by Zacks Equity Research Analyst Blog

Notable Mergers and Acquisitions of the Day 04/30: (BKS)/(MSFT) (SUN)/(ETP) (HOLX)/(GPRO)

4/30/2012 by StreetInsider.com

Pall Corp. says considering share repurchase, dividend enhancement

4/30/2012 by Theflyonthewall.com

Pall to Sell Blood Collection, Filtration, Processing Assets to Haemonetics for $550M

4/30/2012 by Genetic Engineering News

Stocks to Watch: Stocks to watch Monday: Haemonetics, Merck

4/30/2012 by MarketWatch

Haemonetics acquires Hemerus Medical for up to $27M, to pay in stages

4/29/2012 by Theflyonthewall.com

Haemonetics sees FY13 EPS $3.30-$3.40, consensus $3.50

4/29/2012 by Theflyonthewall.com

Haemonetics sees FY13 gross margin of 52-53%,

4/29/2012 by Theflyonthewall.com

Haemonetics sees FY13 organic revenue to be approximately 4-6%

4/29/2012 by Theflyonthewall.com

Haemonetics to acquire Hemerus Medical

4/29/2012 by Theflyonthewall.com

Pall Corp. to record a $1.95-$2.04 per share upon closing asset sale

4/29/2012 by Theflyonthewall.com

Haemonetics Reports 10% Revenue Growth for Fourth Quarter of Fiscal 2012 and $0.80 Adjusted EPS; Also Establishes Fiscal 2013 Guidance

4/29/2012 by StockHouse

Haemonetics Reports 10% Revenue Growth for Fourth Quarter of Fiscal 2012 and $0.80 Adjusted EPS; Also Establishes Fiscal 2013 Guidance

4/29/2012 by StockWatch

Haemonetics Changes Timing of Fourth Quarter and Year End Fiscal Year 2012 Webcast: April 30, 2012 at 8:00 am Eastern Time

4/29/2012 by PR Newswire

Haemonetics Reports 10% Revenue Growth for Fourth Quarter of Fiscal 2012 and $0.80 Adjusted EPS; Also Establishes Fiscal 2013 Guidance

4/29/2012 by PR Newswire

Haemonetics initiated with a Market Perform at Raymond James

4/25/2012 by Theflyonthewall.com

Haemonetics Sets Date for Fourth Quarter and Year End Fiscal Year 2012 Earnings Release: April 30, 2012

4/5/2012 by PR Newswire

Stock Charts to Watch for Bulls AND Bears

3/28/2012 by InvestorPlace

Haemonetics Sets Date for Investor/Analyst Meeting

3/9/2012 by PR Newswire

Haemonetics Reaffirmed at Neutral

3/2/2012 by Zacks Equity Research Analyst Blog

Haemonetics Reaffirmed at Neutral - Analyst Blog

3/2/2012 by Zacks Investment Research

Dave Helsel Joins Haemonetics as Vice President of Global Manufacturing

2/24/2012 by StockHouse

Dave Helsel Joins Haemonetics as Vice President of Global Manufacturing

2/24/2012 by StockWatch

Dave Helsel Joins Haemonetics as Vice President of Global Manufacturing

2/24/2012 by PR Newswire

Haemonetics to Present at Citi 2012 Global Healthcare Conference

2/15/2012 by PR Newswire

Haemonetics to Present at Leerink Swann 2012 Global Healthcare Conference

2/6/2012 by PR Newswire

Haemonetics wins plasma contract extensions

1/30/2012 by Pittsburgh Business Times - Pittsburgh PA

Haemonetics Corp. (HAE) Tops Q3 EPS by 6c; Affirms FY12 EPS Outlook

1/30/2012 by StreetInsider.com

Haemonetics sees FY12 EPS $3.00-$3.10 vs. consensus $3.06

1/30/2012 by Theflyonthewall.com

Haemonetics Corp. (HAE) Tops Q3 EPS by 6c; Guides FY12 EPS

1/30/2012 by StreetInsider.com

Haemonetics Q3 Plasma Disposables revenue rose 15% to $69M

1/30/2012 by Theflyonthewall.com

Haemonetics reports Q3 EPS 86c vs. consensus 80c

1/30/2012 by Theflyonthewall.com

Haemonetics Reports 8% Revenue Growth for Third Quarter of Fiscal 2012 and $0.86 Adjusted EPS; Announces Multi-Year Contract Extensions With Key Plasma Collection Customers; And Affirms Fiscal 2012 Guidance

1/30/2012 by PR Newswire

Haemonetics Corp. (HAE) President & CEO Brian Concannon sells 5,000 Shares

1/5/2012 by GuruFocus
See More Articles...